Xofigo Results Published in New England Journal of Medicine – Explanatory Video Accompanies Publication
The New England Journal of Medicine has just published results from the clinical trial known as ALSYMPCA—a multinational, double-blind, randomized, placebo-controlled Phase III evaluation of the drug marketed as Xofigo—showing improved survival, better quality of life for men who received the drug.
The Prostate Cancer Foundation has repeatedly reported on this drug’s development and movement to market, the approval by the Food and Drug Administration this spring, and the findings show the drug not only extends survival time for men with metastatic prostate cancer that has spread to bone, but also markedly improves their quality of life.
Additionally Prostate Cancer Foundation Young Investigator Neha Vapiwala, MD co-wrote an editorial the accompanied the study. Being asked to opine on such an important study is a great honor and we congratulate not only Dr. Vapiwala, but all the dedicated researchers who worked so hard to bring this drug to market and the seed funding provided by PCF donors that paved the way for the eventual marketing of Xofigo.